文献速递冠心病血脂与心血管预防

秋水仙碱用于血管事件二级预防:随机试验荟萃分析

Colchicine for secondary prevention of vascular events: a meta-analysis of trials.
PubMed 文献 · Eur Heart J · 2025-01-01

该研究对9项随机对照试验(共30 659例已知冠心病或卒中患者)进行荟萃分析,比较秋水仙碱与不用秋水仙碱在动脉粥样硬化性心血管疾病二级预防中的效果。

要点

  • 秋水仙碱使主要复合终点风险降低12%。
  • 心肌梗死风险显著降低,心血管死亡和卒中风险无显著差异。
  • 胃肠道事件住院风险增加,未增加肺炎、新发癌症或非心血管死亡。

核心结论

  • 在已知冠心病或卒中患者中,秋水仙碱将心血管死亡、心肌梗死或卒中的复合终点风险降低12%。

研究设计与样本

  • 系统综述和试验水平荟萃分析,纳入9项随机对照试验,共30 659例患者(秋水仙碱组15 255例,无秋水仙碱组15 404例),采用固定效应逆方差模型,基于意向性治疗人群。

临床怎么用

  • 对于既往冠心病或卒中的动脉粥样硬化性心血管疾病患者,可考虑使用秋水仙碱进行二级预防以降低复合心血管事件风险。
  • 使用秋水仙碱时需关注胃肠道事件导致的住院风险增加。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Randomized trials of colchicine in secondary prevention of atherosclerotic cardiovascular disease have shown mixed results. METHODS: A systematic review and study-level meta-analysis of randomized controlled trials was performed comparing colchicine vs no colchicine in a secondary-prevention atherosclerotic cardiovascular disease population. A fixed-effect inverse variance model was applied using the intention-to-treat population from the included trials. The primary outcome was the composite of cardiovascular death, myocardial infarction, or stroke. RESULTS: Nine trials, including 30 659 patients (colchicine 15 255, no colchicine 15 404) with known coronary artery disease or stroke, were included. Compared with no colchicine, patients randomized to colchicine had a relative risk (RR) of 0.88 [95% confidence interval (CI) 0.81-0.95, P = .002] for the primary composite outcome, including a RR of 0.94 for cardiovascular death (95% CI 0.78-1.13, P = .5), a RR of 0.84 for myocardial infarction (95% CI 0.73-0.97, P = .016), and a RR of 0.90 for stroke (95% CI 0.80-1.02, P = .09). Colchicine was associated with a RR of 1.35 for hospitalization for gastrointestinal events (95% CI 1.10-1.66, P = .004) with no increase in hospitalization for pneumonia, newly diagnosed cancers, or non-cardiovascular death. CONCLUSIONS: In patients with prior coronary disease or stroke, colchicine reduced the composite of cardiovascular death, myocardial infarction, or stroke by 12%.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. d'Entremont MA, Poorthuis MHF, Fiolet ATL, et al. Colchicine for secondary prevention of vascular events: a meta-analysis of trials. Eur Heart J. 2025. PMID: 40314334. doi:10.1093/eurheartj/ehaf210

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。